Navigation Links
Pharmasset Reports Fiscal First Quarter 2009 Financial Results
Date:2/9/2009

smith@pharmasset.com>richard.smith@pharmasset.com Office: +1 (609) 613-4181

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation,, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Annual Report on Form 10-K for the fiscal year ended September 30, 2008 and our Quarterly Report on Form 10-Q for the period ended December 31, 2008 filed with the Securities and Exchange Commission entitled "Risk Factors" and discussions of potential risks and uncertainties in our subsequent filings with the Securities and Exchange Commission.

                            PHARMASSET, INC.
      CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE NET LOSS
                               (UNAUDITED)

                                               Three Months Ended
                                                  December 31,
                                                  ------------
                                               2008          2007
             
'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Pharmasset Announces $45.5 Million Registered Direct Offering of Common Stock
2. Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
3. Pharmasset to Present at Two Upcoming Investor Conferences
4. Pharmasset to Present at the Natixis Bleichroeder Hidden Gems Conference on Monday, October 13th
5. Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th
6. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
7. Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
8. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
9. Pharmasset Announces $25.9 Million Registered Direct Offering of Common Stock
10. Pharmasset Joins Russell 3000 Index
11. Pharmasset to Present at the Needham & Co. Biotechnology and Medical Technology Conference on Wednesday, June 11th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Mass. , Jan. 14, 2014  RXi Pharmaceuticals ... discovering, developing and commercializing innovative therapies addressing major ... that it received the Notice of Allowance from ... its unique self-delivering RNAi compounds (sd-rxRNA®), for the ...
(Date:1/14/2014)... ®, provider of RapidResponse ®, a cloud-based supply chain ... S&OP ) service, is proud to be a gold sponsor ... at the Hilton San Diego Bayfront, January 30 – 31, ... , Director of Supply Chain at Amgen, as she presents ...
(Date:1/14/2014)... Orange, CA (PRWEB) January 14, 2014 Kerr ... a 10-minute video and additional how-to information about dual arch ... Great Restorations with Dual Arch Impressions,” the blog entry serves ... the technique and houses a step-by-step demonstration by Dr. David ...
(Date:1/14/2014)... Independent publisher Bitingduck Press, with offices in ... big ideas for 2014 in production and sales of ... produce high-quality, low-cost, DRM-free ebooks and to use the ... The first major development will be bookstore sales in ...
Breaking Biology Technology:RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
... Benefits of GMO Foods Versus Organic Food featured in Conversations about ... ... MO (PRWEB) August 11, 2008 -- Today, the Conversations about Plant ... produced by other organizations. The first addition -- "What,s for ...
... Aug. 11 /Xinhua-PRNewswire-FirstCall/ --,Kiwa Bio-Tech Products Group Corporation ... quarter of 2008 ended June 30 were,$3,027,497 an ... the second,quarter of 2007. Revenues for the first ... the previous year., The significant revenue improvement ...
... Acquisition will bring together two complementary technologies to extend, reach ... ... -, CINCINNATI, Aug. 11 Ethicon Endo-Surgery announced,today that ... a,privately held developer of the advanced bipolar tissue sealing system ...
Cached Biology Technology:Is GMO Food and Organic Food an Either/Or Proposition? 2Is GMO Food and Organic Food an Either/Or Proposition? 3Kiwa Bio-Tech 2nd Quarter Revenues Increase 61.7% to $3 Million, Six Month Revenues Top $5.2 Million 2Kiwa Bio-Tech 2nd Quarter Revenues Increase 61.7% to $3 Million, Six Month Revenues Top $5.2 Million 3Kiwa Bio-Tech 2nd Quarter Revenues Increase 61.7% to $3 Million, Six Month Revenues Top $5.2 Million 4Kiwa Bio-Tech 2nd Quarter Revenues Increase 61.7% to $3 Million, Six Month Revenues Top $5.2 Million 5Kiwa Bio-Tech 2nd Quarter Revenues Increase 61.7% to $3 Million, Six Month Revenues Top $5.2 Million 6Kiwa Bio-Tech 2nd Quarter Revenues Increase 61.7% to $3 Million, Six Month Revenues Top $5.2 Million 7Kiwa Bio-Tech 2nd Quarter Revenues Increase 61.7% to $3 Million, Six Month Revenues Top $5.2 Million 8Kiwa Bio-Tech 2nd Quarter Revenues Increase 61.7% to $3 Million, Six Month Revenues Top $5.2 Million 9Ethicon Endo-Surgery to Acquire SurgRx 2Ethicon Endo-Surgery to Acquire SurgRx 3
(Date:4/22/2014)... have presented Beaumont Health System with prestigious, competitive ... both athletic and nonathletic injuries. , The ... $40,000 grant to fund stem cell-based research that ... a ruptured knee anterior cruciate ligament, or ACL. ... anterior cruciate ligament injury is the over-stretching or ...
(Date:4/22/2014)... the University of Kentucky has discovered new methods to ... , The research, led by Peixuan Guo, professor and ... UK College of Pharmacy and Markey Cancer Center, is ... Anionic Polymer Material To Build Robust Structures with Defined ... Daniel L. Jasinski. , The article, which will appear ...
(Date:4/22/2014)... thousands of breeding bird surveys sent in by citizen ... 35 years, wildlife researchers report that most of the ... toward higher elevation in response to climate change, but ... most previous studies of potential climate change impacts on ... other have likely underestimated the effects of environmental warming, ...
Breaking Biology News(10 mins):Beaumont awarded grants to study sports-related injury treatment, improve recovery 2RNA shows potential as boiling-resistant anionic polymer material for nanoarchitectures 2Wildlife response to climate change is likely underestimated, experts warn 2
... has developed a computer model that makes use of ... movements to explain how the brain draws on both what ... to anticipate what it needs to develop new motor skills. ... the fact that all people show similar “probable” learning patterns ...
... smoking causes cancer, but new research shows that children could ... , Canadian researchers have demonstrated in mice that smoking can ... that could potentially be inherited by offspring. The results of ... Cancer Research, a journal of the American Association for Cancer ...
... While orange cauliflower may seem unappealing to some, it ... the genetic mutation behind the unusual hue. The finding ... potato, rice, sorghum and wheat. , The genetic ... and colleagues -- and described in the December issue ...
Cached Biology News:Math that powers spam filters used to understand how brain learns to move our muscles 2Cigarette smoke alters DNA in sperm, genetic damage could pass to offspring 2Discovery in orange cauliflower may lead to more nutritious crops 2